Regional DTI differences in multiple sclerosis patients
Stefan D. Roosendaal(Amsterdam University Medical Centers), Frederik Barkhof(Netherlands Institute for Neuroscience), Hanneke E. Hulst(Amsterdam UMC Location Vrije Universiteit Amsterdam), Petra Pouwels(Amsterdam UMC Location VUmc), Jonas A. Castelijns(Alkermes (Ireland)), Keith S. Cover(University Medical Center), Hugo Vrenken(Amsterdam Neuroscience), José W. Geurts(University Medical Center)
Cited by 369
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k